antibody drug conjugate

FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...

LOS ANGELES, Calif., June 18, 2026 TORL BioTherapeutics has reported encouraging preliminary Phase 1 clinical data for its investigational...

SHANGHAI & CAMBRIDGE, Mass., June 16, 2026 Zai Lab announced that the European Medicines Agency (EMA) has granted Orphan...

BOTHELL, Wash., June 11, 2026 Immunome, Inc. announced the first patient has been dosed in a Phase 1 first-in-human...

NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...

REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...

BOSTON, June 1, 2026 Servier has announced encouraging new clinical findings for Emiltatug Ledadotin (Emi-Le), an investigational B7-H4-targeted antibody-drug...

SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...

NORTH CHICAGO, Ill., May 27, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ™...